Plaque Reversal With Early, Aggressive Lipid Lowering Therapy (EAGLE)
Study Overview
Status
Status
Conditions
Conditions
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Erik SG Stroes, MD, PhD
- Phone Number: +205669111
- Email: e.s.stroes@amsterdamumc.nl
Study Locations
-
-
North Holland
-
Amsterdam, North Holland, Netherlands, 1105 AZ
- Recruiting
- Amsterdam UMC, location AMC
-
Contact:
- Erik S. G. Stroes, MD, PhD
- Phone Number: +31205669111
- Email: e.s.stroes@amsterdamumc.nl
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Diagnosed with heterozygous familial hypercholesterolemia
- Adult between 18 and 50 years old
- LDL cholesterol levels above 100 mg/dl (>2.6 mmol/L) at inclusion
Exclusion Criteria:
- Renal insufficiency, defined as eGFR < 30 ml/min
- History of atherosclerotic cardiovascular events
- Atrial fibrillation
- Any other treatment or clinically relevant condition that could interfere with the conduct or interpretation of the study in the opinion of the investigator
- Inability or unwillingness to comply with the protocol requirements, or deemed by investigator to be unfit for the study.
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
CAD Progression
Time Frame: 40 Weeks
|
Difference in total plaque volume between the initial and follow-up CCTA scan
|
40 Weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Non-calcified plaque progression
Time Frame: 40 Weeks
|
Difference in non-calcified plaque volume between the baseline and follow-up CCTA scan
|
40 Weeks
|
|
Calcified plaque progression
Time Frame: 40 Weeks
|
Difference in calcified plaque volume between the baseline and follow-up CCTA scan
|
40 Weeks
|
|
Number of high-risk plaques
Time Frame: 40 Weeks
|
Difference in number of high-risk plaques between the baseline and follow-up CCTA scan
|
40 Weeks
|
|
Difference in Pericoronary Adipose Tissue Attenuation
Time Frame: 40 Weeks
|
Difference in Pericoronary Adipose Tissue Attenuation between the baseline and follow-up CCTA scan
|
40 Weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Erik SG Stroes, MD, PhD, Amsterdam UMC, location AMC
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Estimated)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- NL75337.018.20
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.